key: cord-0882411-jnjbhncc
authors: Schaefer-Prokop, Cornelia; Prokop, Mathias
title: Chest Radiography in COVID-19: No Role in Asymptomatic and Oligosymptomatic Disease
date: 2020-12-08
journal: Radiology
DOI: 10.1148/radiol.2020204038
sha: 023ded4ed61e267198125a9b832277685f2dbae6
doc_id: 882411
cord_uid: jnjbhncc

nan

During the first peak of the pandemic, there has been a vivid and controversial discussion about the role of imaging for the diagnosis of COVID-19. Early publications from China had reported typical CT findings for pulmonary involvement of COVID-19 (1, 2) , even in patients with an initially negative reverse-transcription polymerase chain reaction (RT-PCR). Triggered by these reports, CT was used in various settings, from pre-operative screening of asymptomatic patients to triage of patients with clinical symptoms. This was usually done in cases with negative or not yet available RT-PCR results or in situations of constrained availability of laboratory tests or clinical care facilities.

A lesser focus was initially set on chest radiographs due to their lower sensitivity to diagnose subtle parenchymal abnormalities and their limited ability to differentiate parenchymal patterns that might provide keys for differential diagnosis. However, chest radiography is readily and widely available, and its ease of use sets a low threshold for application in various COVID-19 settings.

Little has been published about the role of CXR as a function of duration and severity of symptoms. An Italian group studied the effect of duration of symptoms on false negative rate (FNR) of CXR in a mixed group of 240 confirmed COVID-19 cases. They found an overall FNR of 25%, which increased to 63% in the first two days after symptom onset and still remained 16% more than 9 days after symptom onset (3) . No analysis, however, was performed depending on the severity of symptoms The current work by Kuo et al represents the first larger study describing the role of chest radiography (CXR) in a cohort of almost 2000 patients with confirmed COVID-19 but no or minimal symptoms (4) . They demonstrate that CXR is not useful in these patients if there are no risk factors for disease progression or worsening of respiratory status. CXR is therefore not recommended for baseline screening diagnostics in such low-risk individuals.

Clinical presentation and symptoms of COVID-19 widely vary in frequency and severity. The WHO divided patients with COVID-19 infection into six types of disease severity: uncomplicated illness, mild pneumonia, severe pneumonia, ARDS, sepsis and septic shock (5) . It has been estimated that up to half of persons infected with SARS-CoV-2 remain oligo-symptomatic or asymptomatic. While most people present with mild or uncomplicated illness (no need for supplemental oxygen), up to 15% of patients may develop severe disease requiring hospitalization and oxygen support and up to 5% may require admission to an intensive care unit (ICU). Older age and comorbidities represent risk factors for worse outcome. Symptoms may initially be absent but develop over time with disease progression.

The role of laboratory tests and imaging thus not only depends on the clinical status of the patient but also on regional disease prevalence and local availability of laboratory and clinical facilities including intensive care treatment. The Multinational Consensus statement from the Fleischner Society about the role of imaging, published in April 2020, specifically addressed these varying facets (6) . A diagnostic tree was proposed for three clinical scenarios with increasing urgency (mild features, moderate-to-severe features and moderate-to-severe features in a resource constrained environment), clearly defining under which conditions imaging is indicated. The evidence about the use of imaging within these scenarios was scant at time of publication and sometimes even controversial. The statement thus represented the collective opinions and perspectives of a multidisciplinary group that included clinical, laboratory and infection control experts, as well as radiologists from 10 countries. To include new evidence in the rapidly changing environment of the pandemic, the first author, G. Rubin, was invited by the RSNA to present more recent publications after April 2020 in a publicly available webinar (7) coming to the conclusion that the statement is still valid as it is.

The study by Kuo et al refers to scenario 1 in the Fleischner statement and now provides scientific evidence for this recommendation: in COVID 19 patients with mild features of infection and no risk factors for disease progression, imaging is only indicated if respiratory status worsens during selfmonitoring. It is not suited as a baseline screening test.

The current study analyzed the value of a screening chest radiograph obtained among a large group of over 5000 young and middle-aged adults with RT-PCR proven COVID-19 infection and no or mild symptoms. Mild symptoms were defined as "absence of significant pulmonary dysfunction or damage" following WHO criteria. All patients had been admitted to a so-called community care facility (CCF) on the area of the Singapore Expo to ensure adequate isolation and basic medical surveillance that would trigger hospitalization and more intense treatment on demand. During CCF stay, patients were required to submit vital parameters daily, including heart rate, blood pressure, and oxygen saturation at self-monitoring stations. In addition there were sickbay centers that operated like primary care clinics in daytime and virtual telecommunication medical stations staffed by doctors 24/7.

Baseline CXR was performed if was older than older than 36 years and no imaging had been done previously or if respiratory symptoms were reported at admission or during the CCF stay (in n=1,964). Abnormal findings were seen on the baseline chest radiograph in only 39 patients. Fourteen of these patients were hospitalized because symptoms were present within a week, but none of them subsequently required supplemental oxygen or IV treatment. Another 8 of the 39 patients were transferred to the hospital because of worsening of respiratory symptoms, of which four subsequently required supplemental oxygen and two were transferred to intensified care. No patient died. This meant that prognosis was excellent and the rate of hospitalization was very low in this group with none or only mild symptoms, an average age of 37 years and a negligible rate of comorbidities. Deterioration was seen in this low-risk group within the first week of symptoms, which differs from reports in higher-risk populations that found clinical deterioration mainly in the second week after symptom onset (8) . While a normal baseline CXR did not completely exclude future respiratory or non-respiratory symptoms, the event rate was very small (2 / 1,925 and 24 / 1,925 patients, respectively). However, it has to be noted that the low rate of symptoms was selfreported and might have been biased.

The study by Kuo et al et al does not touch upon the second part of the Fleischner criteria described for scenario 1, in which indication for imaging is described for patients with risk factors for disease progression. Higher age and a number of comorbidities such as diabetes, cardiovascular disease, hypertension and obstructive lung disease have been found to worsen the prognosis and outcome of COVID-19 infection (8) . In this context it would be interesting to know whether the 8 patients with pathological baseline chest radiograph and worsening respiratory symptoms were suffering from such risk factors that would have helped to predict risk of deterioration. However, "information on chronic diseases in the study group was low" (5). It can be assumed that comorbidities in the study were rare or mild because part of the CCF admission criteria was "the absence of medical indications or comorbidities requiring inpatient care". The study therefore does not provide evidence for an imaging indication in a high-risk group with mild symptoms of COVID-19.

A relatively large group of patients admitted to the CCF had undergone previous chest imaging (n=1,363) and unfortunately no information is provided on potential reasons, such as age or symptoms. Therefore a selection bias cannot be completely excluded.

In summary, the work by Kuo et al provides clear evidence for the Fleischner statement that baseline imaging is not indicated if symptoms are absent or mild and there are no risk factors for disease progression. There is, however, still need for evidence of the Fleischner statement about the need for imaging in patients with mild symptoms and coexisting risk factors for disease progression. This would allow us to better understand if and how imaging affects management decisions in this common patient group.

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: A meta-analysis

Radiographic findings in 240 patients with COVID-19 pneumonia: time dependence after the onset of symptoms

Utility of Screening Chest Radiographs in Patients with Asymptomatic or Minimally Symptomatic COVID-19 in Singapore

Clinical management of COVID-19

The Role of Chest Imaging in Patient Management during the COVID19 Pandemic: A Multinational Consensus Statement from the Fleischner Society

Chest imaging during the COVID-19 Pandemic: An Update

Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study